Ginkgo Bioworks

Ginkgo Bioworks reported Q2 2026 revenue of $20 million, missing the consensus estimate of $29.9 million; revenue thus fell 48% year over year. Adjusted EPS of -$0.92 beat expectations but could not offset the negative market reaction, and the stock fell about 4.9% after the close. The company emphasizes its focus on autonomous labs, reports total liquidity of $389 million and confirms a 2026 cash burn guidance of $125–150 million. » More on de.investing.com

Ginkgo Bioworks has introduced the Ginkgo Cloud Lab platform, a web-based interface for remote access to its modular, robot-assisted lab infrastructure with over 70 instruments. The platform uses reconfigurable automation carts, maglev tracks and an AI agent called EstiMate that reviews protocols written in natural language and provides pricing and compatibility information. The rollout is intended as part of the 2026 strategy to shift research and development services to the autonomous lab Nebula and to replace traditional lab benches with robotic infrastructure. The stock faces short-term headwinds after recent price losses, but analysts currently consider it undervalued. » More on de.investing.com

Ginkgo Bioworks and Invaio Sciences have agreed a partnership to develop microbial strains for the industrial production of peptide-based crop protection solutions. Ginkgo will deploy its platform, genetically engineered strains and autonomous lab infrastructure to scale Invaio’s fermentation processes and production targets. The aim is to make peptides available as a biological alternative to conventional pesticides against resistant pests. With this, Ginkgo is focusing on support from strain development through bioprocess development for agricultural solutions. » More on de.investing.com